Our article compares the clinical development success rates of durable cell and gene therapies (dCGTs) from 1988 to 2023 with BIO and IQVIA’s published benchmarks for all therapeutic modalities. As FDA-approved dCGTs grow from 0 to 30 since 2017, the article offers valuable insights into how these therapies are performing in clinical trials compared to other drug categories.

Learn about the promising success rates of dCGTs, especially in rare disease treatments, and what this means for the future of gene therapies.

The research for the Nature Reviews article was supported by a grant from the Alliance for Regenerative Medicine.

Read the article on Nature Reviews Drug Discovery